Title:
IMMUNOGENIC PEPTIDES AND USE THEREOF IN IMMUNE DISORDERS
Document Type and Number:
Japanese Patent JP2015142578
Kind Code:
A
Abstract:
PROBLEM TO BE SOLVED: To provide novel immunogenic peptides and homologs thereof for prevention or treatment of allergy or autoimmune diseases.SOLUTION: Provided is a method of identifying population of CD4+ cytotoxic T cells against the antigen presenting cells, where the method identifies T cells expressing CD4, not expressing IL-10 or TGF-beta, expressing Knox-20 and forming granzyme and Fas ligand. The immunogenic peptides of the invention comprise a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction when presented by a class II major histocompatibility complex (MHC) determinant and recognized by CD4+ T cells, more specifically, a T-cell epitope of an allergen or auto-antigen which is coupled through a linker to an amino acid sequence having a reducing activity, such as a thioreductase sequence.
Inventors:
JEAN-MARIE SAINT-REMY
Application Number:
JP2015040819A
Publication Date:
August 06, 2015
Filing Date:
March 03, 2015
Export Citation:
Assignee:
LIFE SCIENCES RES PARTNERS VZW
UNIV LEUVEN KATH
UNIV LEUVEN KATH
International Classes:
C12Q1/04; A61K35/17; A61K38/00; A61K39/00; A61K39/35; A61P3/10; A61P25/00; A61P37/02; A61P37/08; C07K14/705; C07K19/00; C12N5/0783; C12N15/09
Domestic Patent References:
| JP2005536987A | 2005-12-08 |
Other References:
JPN6016005771; ＦＥＨＥＲＶＡＲＩ， Ｚ． ｅｔ ａｌ．: '"ＣＤ４＋ Ｔｒｅｇｓ ａｎｄ ｉｍｍｕｎｅ ｃｏｎｔｒｏｌ．"' Ｊ． ＣＬＩＮ． ＩＮＶＥＳＴ． Ｖｏｌ．１１４， Ｎｏ．９, 200411, Ｐ．１２０９-１２１７
JPN6016005758; ＪＡＮＳＳＥＮＳ， Ｗ． ｅｔ ａｌ．: '"ＣＤ４＋ＣＤ２５＋ Ｔ ｃｅｌｌｓ ｌｙｓｅ ａｎｔｉｇｅｎ-ｐｒｅｓｅｎｔｉｎｇ Ｂ ｃｅｌｌｓ ｂｙ Ｆａｓ-Ｆａｓ ｌｉｇａｎｄ ｉｎｔｅｒａｃｔｉｏｎ ｉｎ ａｎ ｅｐｉｔｏｐｅ-ｓｐｅｃｉ' Ｊ． ＩＭＭＵＮＯＬ． Ｖｏｌ．１７１， Ｎｏ．９, 20031101, Ｐ．４６０４-４６１２
JPN6016005760; ＨＡＲＲＩＳ， Ｊ．Ｅ． ｅｔ ａｌ．: '"Ｅａｒｌｙ ｇｒｏｗｔｈ ｒｅｓｐｏｎｓｅ ｇｅｎｅ-２， ａ ｚｉｎｃ-ｆｉｎｇｅｒ ｔｒａｎｓｃｒｉｐｔｉｏｎ ｆａｃｔｏｒ， ｉｓ ｒｅｑｕｉｒｅｄ ｆｏｒ ｆｕｌｌ ｉｎｄｕｃｔｉｏｎ ｏｆ' Ｊ． ＩＭＭＵＮＯＬ． Ｖｏｌ．１７３， Ｎｏ．１２, 20041215, Ｐ．７３３１-７３３８
JPN6016005763; ＭＩＴＴＥＬＳＴＡＤＴ， Ｐ．Ｒ． ｅｔ ａｌ．: '"Ｒｏｌｅ ｏｆ Ｅｇｒ-２ ｉｎ ｕｐ-ｒｅｇｕｌａｔｉｏｎ ｏｆ Ｆａｓ ｌｉｇａｎｄ ｉｎ ｎｏｒｍａｌ Ｔ ｃｅｌｌｓ ａｎｄ ａｂｅｒｒａｎｔ ｄｏｕｂｌｅ-ｎｅｇａｔｉｖｅ ｌｐｒ ａｎｄ' Ｊ． ＢＩＯＬ． ＣＨＥＭ． Ｖｏｌ．２７４， Ｎｏ．５, 19990129, Ｐ．３２２２-３２２７
JPN6016005768; ＨＡＨＮ， Ｓ． ｅｔ ａｌ．: '"Ｍｅｃｈａｎｉｓｍ ａｎｄ ｂｉｏｌｏｇｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ ｏｆ ＣＤ４-ｍｅｄｉａｔｅｄ ｃｙｔｏｔｏｘｉｃｉｔｙ．"' ＩＭＭＵＮＯＬ． ＲＥＶ． Ｖｏｌ．１４６, 199508, Ｐ．５７-７９
JPN6016005758; ＪＡＮＳＳＥＮＳ， Ｗ． ｅｔ ａｌ．: '"ＣＤ４＋ＣＤ２５＋ Ｔ ｃｅｌｌｓ ｌｙｓｅ ａｎｔｉｇｅｎ-ｐｒｅｓｅｎｔｉｎｇ Ｂ ｃｅｌｌｓ ｂｙ Ｆａｓ-Ｆａｓ ｌｉｇａｎｄ ｉｎｔｅｒａｃｔｉｏｎ ｉｎ ａｎ ｅｐｉｔｏｐｅ-ｓｐｅｃｉ' Ｊ． ＩＭＭＵＮＯＬ． Ｖｏｌ．１７１， Ｎｏ．９, 20031101, Ｐ．４６０４-４６１２
JPN6016005760; ＨＡＲＲＩＳ， Ｊ．Ｅ． ｅｔ ａｌ．: '"Ｅａｒｌｙ ｇｒｏｗｔｈ ｒｅｓｐｏｎｓｅ ｇｅｎｅ-２， ａ ｚｉｎｃ-ｆｉｎｇｅｒ ｔｒａｎｓｃｒｉｐｔｉｏｎ ｆａｃｔｏｒ， ｉｓ ｒｅｑｕｉｒｅｄ ｆｏｒ ｆｕｌｌ ｉｎｄｕｃｔｉｏｎ ｏｆ' Ｊ． ＩＭＭＵＮＯＬ． Ｖｏｌ．１７３， Ｎｏ．１２, 20041215, Ｐ．７３３１-７３３８
JPN6016005763; ＭＩＴＴＥＬＳＴＡＤＴ， Ｐ．Ｒ． ｅｔ ａｌ．: '"Ｒｏｌｅ ｏｆ Ｅｇｒ-２ ｉｎ ｕｐ-ｒｅｇｕｌａｔｉｏｎ ｏｆ Ｆａｓ ｌｉｇａｎｄ ｉｎ ｎｏｒｍａｌ Ｔ ｃｅｌｌｓ ａｎｄ ａｂｅｒｒａｎｔ ｄｏｕｂｌｅ-ｎｅｇａｔｉｖｅ ｌｐｒ ａｎｄ' Ｊ． ＢＩＯＬ． ＣＨＥＭ． Ｖｏｌ．２７４， Ｎｏ．５, 19990129, Ｐ．３２２２-３２２７
JPN6016005768; ＨＡＨＮ， Ｓ． ｅｔ ａｌ．: '"Ｍｅｃｈａｎｉｓｍ ａｎｄ ｂｉｏｌｏｇｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ ｏｆ ＣＤ４-ｍｅｄｉａｔｅｄ ｃｙｔｏｔｏｘｉｃｉｔｙ．"' ＩＭＭＵＮＯＬ． ＲＥＶ． Ｖｏｌ．１４６, 199508, Ｐ．５７-７９
Attorney, Agent or Firm:
Fukami patent office